At its latest capital markets day, distribution giant Brenntag announced ‘Strategy to Win’, its detailed strategic growth plan including new mid-term targets until 2026. It also unveiled a new brand identity. ‘Strategy to Win’ is the second phase of a planned “transformation journey”.
Global Healthcare Opportunities, a European specialist investor in global healthcare, and The Vistria Group, a middle-market private investment firm, have agreed to acquire US-based CDMO Alcami from Madison Dearborn Partners and Ampersand Capital Partners. They will each have 50% stakes.
Eastman has joined forces with Sphera, a long-time supplier, on the next generation of Sphera’s life cycle assessment (LCA) automation software. This was launched earlier in 2022 and seeks to enable businesses “to quickly receive holistic, real-time analysis and insights into the environmental footprint of their product portfolios and integrates seamlessly with their existing systems” and thus reduce their greenhouse gas emissions at every step of production.
HRH Prince Abdulaziz bin Salman Al-Saud, Saudi Arabia’s minister of energy (pictured above), will deliver the inaugural address at the 16th Annual Gulf Petrochemicals & Chemicals Association (GPCA) Forum, which will be held in Riyadh for the first time on 6-8 December 2022. Hosted by SABIC, this year’s forum will be held under the theme ‘Chemistry in Action: Shaping a Sustainable Future.’ The minister will also lead the inaugural panel discussion with other Gulf energy ministers.
Vicky Xia and Joel Ranck of BioPlan share some first insights from the CPHI Annual Report
Having already benefitted from a COVID-based boom in the last two years, outsourcing of biologics globally is set to continue growing significantly in 2023. No production cliff is expected, even as COVID-related contracts reduce in scale, but the rapid growth of China’s biologics sector will slow.
Cambrex has announced it is investing in a new facility in Minneapolis. It will operate as an extension of the flagship facility in Charles City, Iowa (pictured), which is simultaneously seeing further expansion.
The new site, near Minneapolis–St. Paul Airport, will specialise in analytical and chemical development for small molecule drug candidates and will cover 1,950 m2 R&D. This will double Cambrex’s analytical and chemical development footprint in the Midwest, according to CEO Thomas Loewald, while creating 46 jobs.
International Chemical Investors Group (ICIG), the owner of WeylChem and various other chemical operations, has agreed to acquire Inprotec from Paragon Partners and its minority co-shareholders. The transaction is expected to close in November, subject to customary antitrust clearance.
